Several preclinical or retrospective studies have shown that PBRM1 seems to be predictive of immunotherapeutic responses [4, 7, 13], but to date still controversial and unevaluated in the clinical decision-making process [8], which is likely due, in part, to the fact that PBRM1 alone lack the capacity to define a homogenous molecular ccRCC subtype. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.